On January 13, 2025, Medtronic (NYSE: MDT), a global medical technology giant, announced,Its innovative BrainSense adaptive deep brain stimulation (aDBS) technology has successfully obtained CE mark certification. Meanwhile, the company's BrainSense Electrode Identifier (EI) has also been approved. Following the approval, Dr. Martijn Beudel completed the first implantation of this technology in Amsterdam.This medical technology giant stated that this approval and the programming of the first patient in Europe mark a significant advancement in personalized deep brain stimulation (DBS) therapy for the treatment of Parkinson's disease.

Deep Brain Stimulation (DBS) is an advanced neuromodulation technology that involves the precise implantation of electrodes into specific brain regions via surgery, followed by the delivery of electrical signals to regulate abnormal brain activity. This therapy is primarily used in clinical settings to treat Parkinson's disease, severe depression, and a range of movement disorders, demonstrating significant efficacy in alleviating core symptoms such as tremors, muscle rigidity, and bradykinesia in patients with Parkinson's disease.

Medtronic's BrainSense™ Adaptive Deep Brain Stimulation (aDBS) System Achieves Significant Innovation Breakthroughs in Treatment Principles and Outcomes. The system’s standout feature is its closed-loop design, which enables real-time monitoring of a patient’s brain activity and automatically adjusts stimulation parameters based on the monitoring results. This real-time, adaptive regulation capability allows for more personalized treatment that closely follows changes in the patient’s condition, effectively overcoming the limitations of traditional DBS therapy, which often requires frequent manual intervention.

The application of BrainSense™ aDBS technology not only significantly enhances the effectiveness of treatment but also greatly improves patients' quality of life. Particularly in daily life and clinical settings, patients can better adapt to the treatment and experience more stable and continuous symptom relief.

In addition, Medtronic has also launched the BrainSense™ Electrode Identifier as an auxiliary tool to further enhance the efficiency of DBS programming. The electrode identifier can quickly and accurately determine the optimal initial electrode contact point during the DBS implantation process, significantly speeding up the programming process and reducing the adjustment time when initiating treatment. The application of this innovative tool undoubtedly provides clinicians with a more convenient and efficient means of DBS programming.

Medtronic’s BrainSense aDBS Technology, delivered through its Percept Neurostimulator, enables real-time, adaptive treatment. This technology dynamically adjusts stimulation parameters based on each patient’s unique brain activity, both in clinical settings and daily life, providing more precise and personalized therapy. Additionally, BrainSense EI Technology significantly enhances the efficiency and accuracy of DBS programming by quickly identifying the optimal initial contact.

The Percept neurostimulator, equipped with BrainSense technology, can record and analyze patients' brain signals to provide customized treatment tailored to each patient’s unique neural patterns. Medtronic is also actively exploring the integration of Brain-Computer Interface (BCI) technology into its Deep Brain Stimulation (DBS) therapy, aiming to offer more comprehensive solutions in prevention, detection, diagnosis, rehabilitation, and recovery for patients with complex neurological disorders.

Paolo Di Vincenzo, President of the Neuromodulation business in Medtronic's Neuroscience Portfolio, stated: "BrainSense technology is at the core of personalized DBS therapy, and we are advancing this capability through innovations based on our sensing-enabled DBS platform. From improving the precision of contact selection to automatically adjusting DBS therapy, these milestones signify significant progress in providing tailored care for patients with Parkinson’s disease—and this is just the beginning. Our mission is to impact and improve the lives of more patients through Medtronic DBS therapy."

It is reported that Medtronic plans to launch this new DBS technology in Europe in early 2025.At the same time, the company has submitted an application for FDA approval in the United States and is currently awaiting a response.

To further validate the clinical potential of BrainSense aDBS technology, Medtronic is conducting a global multicenter, prospective, single-blind, randomized crossover study named ADAPT-PD.This study aims to evaluate the safety and efficacy of chronic dual-threshold and single-threshold aDBS models compared with continuous DBS in Parkinson's disease patients who meet the criteria for DBS treatment.

Medtronic stated that the ADAPT-PD study is the largest and longest aDBS evaluation trial conducted in a home setting. Researchers monitored participants across four phases over a period of more than one year, including baseline assessment, initial aDBS setup and adjustment, evaluation, and long-term follow-up. Preliminary data showed high brain signals were present in both medication-on and medication-off states, at both DBS target locations, and across all Parkinson’s disease phenotypes.

With BrainSense EI technology, the platform further enhances its precision and efficiency by closely examining each patient’s unique brain signals. It can guide clinicians to the exact location of the strongest signal in a fraction of the time required for standard monopolar review. Medtronic notes that the technology uses local field potentials (LFPs) and α-β activity to determine the optimal contact position, helping achieve more optimized and effective programming compared to standard therapies.

Amaza Reitmeier, Vice President and General Manager of Medtronic's Neuromodulation Marketing and Strategy, stated: "Medtronic remains the world’s first and only company to offer a DBS system with full sensing capabilities, and now we have enhanced this innovation to allow Parkinson’s patients to spend less time thinking about their condition. Patients and clinicians have been eagerly awaiting these BrainSense™ technology enhancements, which represent another transformative step in providing personalized treatment for individuals with Parkinson’s disease."

END

 

More exciting content

Welcome to follow WeChat Video Channel

Instrument Family

Related Reading

Tap for more!

 

$1 Billion: GE Healthcare Secures Largest Order Post-Split

Mindray Invests, China's First ECMO Company Plans IPO

Medtronic Locks Down Next Acquisition Target

Philips, Class I Recall

New Huamei Medical, Sold Again

Win the bid, 70 million RMB per unit

Conorth Medical Completes Over 500 Million RMB Financing

Philips, Selling "The Only One in Europe"

First Chinese-Made, 7T MRI Installed at Nanshan Hospital

United Imaging Healthcare Makes Major Moves in North America

BusinessBusiness cooperation email: qxzj@landianyiliao.com